Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

BRIDGEWATER, NJ / ACCESSWIRE / July 10, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of Jules Haimovitz as a Strategic Advisor to the Company's executive management team.

"We are pleased to have Jules join Tharimmune in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his extensive success in the biotechnology industry, robust professional network and strategic acumen will significantly bolster our clinical and preclinical programs. Particularly noteworthy is our recent positive FDA feedback on the Phase 2 program for TH104. Jules' experience with various clinical-stage companies will be instrumental in setting and navigating the optimal strategy for our pipeline."

Mr. Haimovitz brings decades of biotechnology leadership experience and expertise, including serving on the Boards of Directors of several prominent companies. His comprehensive understanding of corporate governance, strategic planning and industry trends are poised to significantly augment Tharimmune's efforts in delivering innovative treatments to patients with unmet medical needs. His wealth of sector-specific knowledge will prove invaluable as Tharimmune progresses its pipeline of therapeutic candidates, notably TH104, its lead clinical candidate targeting pruritus in patients with primary biliary cholangitis (PBC).

"I look forward to supporting Tharimmune's commitment to developing transformative therapies, a mission that resonates strongly with my longstanding dedication to advancing healthcare solutions. My appointment is strategically timed, particularly given the critical role that Phase 2 testing plays as a significant value inflection point for biopharmaceutical companies and their developmental assets. I look forward to applying my experience and insight to support Tharimmune effectively during this critical phase," added Mr. Haimovitz.

Mr. Haimovitz is currently President of Haimovitz Consulting, Inc. He also serves as a Director of Armata Pharmaceuticals and is a Director of Innoviva. He previously served as Director of Ariad Pharmaceuticals, Dial Global and ImClone Pharmaceuticals. Mr. Haimovitz has also served in various executive management position including as Chief Executive Officer or Chief Operating Officer of Spelling Entertainment, King World Productions and VJN. He holds a BS and MA in mathematics from Brooklyn College.

About Tharimmune

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against these and other specified targets. For more information please visit: www.tharimmune.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.

Contacts:

Tharimmune, Inc.
ir@tharimmune.com

LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614

SOURCE: Tharimmune, Inc.